NF1

MIAMI, USA — April 1, 2026 Pasithea Therapeutics Corp. has announced that the U.S. Food and Drug Administration (FDA)...

Wilmington, Delaware, November 2025 AstraZeneca has announced that Koselugo (selumetinib) has received expanded FDA approval in the United States...

MIAMI, November 4, 2025: Pasithea Therapeutics Corp. has announced the activation of a new clinical trial site at the...